159 related articles for article (PubMed ID: 21445544)
1. Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab.
Studer U; Ruehe B; Waldegg G; Vajtai I; Escher R; Aeberli D
Rheumatol Int; 2012 May; 32(5):1431-5. PubMed ID: 21445544
[TBL] [Abstract][Full Text] [Related]
2. Refractory neuro-Behçet treated by tocilizumab: a case report.
Urbaniak P; Hasler P; Kretzschmar S
Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
[TBL] [Abstract][Full Text] [Related]
3. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
Sarwar H; McGrath H; Espinoza LR
J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
[No Abstract] [Full Text] [Related]
6. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
Yalcin Kehribar D; Gunaydin S; Ozgen M
Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
[TBL] [Abstract][Full Text] [Related]
7. Life-threatening vasculo-Behçet following discontinuation of infliximab after three years of complete remission.
Magro-Checa C; Salvatierra J; Rosales-Alexander JL; Orgaz-Molina J; Raya-Álvarez E
Clin Exp Rheumatol; 2013; 31(3 Suppl 77):96-8. PubMed ID: 23739315
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
[TBL] [Abstract][Full Text] [Related]
10. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
11. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
[TBL] [Abstract][Full Text] [Related]
12. "Fulminant" Behçet disease.
Zaidan M; Lidove O; Sacré K; Klein I; Papo T
Presse Med; 2011 Nov; 40(11):1087-9. PubMed ID: 21658901
[No Abstract] [Full Text] [Related]
13. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
14. Neuro-Behçet's disease mimicking a cranial tumour.
Senol S; Ucar M; İmamoğlu H; Yildirim A
BMJ Case Rep; 2015 Jun; 2015():. PubMed ID: 26101297
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
[TBL] [Abstract][Full Text] [Related]
16. [Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].
Kadowaki S; Matsuda N; Moriya A; Ebitani M; Yoshihara A; Nakamura K; Mochizuki H; Ugawa Y
Rinsho Shinkeigaku; 2011 Apr; 51(4):261-6. PubMed ID: 21595295
[TBL] [Abstract][Full Text] [Related]
17. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for patients with neuro-Behcet's disease: case series and literature review.
Borhani Haghighi A; Safari A; Nazarinia MA; Habibagahi Z; Shenavandeh S
Clin Rheumatol; 2011 Jul; 30(7):1007-12. PubMed ID: 21431864
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
[TBL] [Abstract][Full Text] [Related]
20. Neurological complications of Behçet's syndrome.
Kidd D
Curr Neurol Neurosci Rep; 2012 Dec; 12(6):675-9. PubMed ID: 23007835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
